Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12734860 | 0.97 | GAA (0.32) | GAAMAPTMEN1KMT2A | |
| SCHEMBL12739665 | 0.97 | GAA (0.32) | GAAMAPTMEN1KMT2A | |
| SCHEMBL7728037 | 0.93 | MAPT (0.36) | GAAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL1574929 | 0.93 | MAPT (0.36) | GAAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL2604707 | 0.93 | MAPT (0.36) | GAAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL7728041 | 0.93 | MAPT (0.36) | GAAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL7728045 | 0.93 | MAPT (0.36) | GAAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL3269906 | 0.93 | MAPT (0.36) | GAAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL30450387 | 0.93 | MAPT (0.36) | GAAMAPTMEN1KMT2ANPC1 | |
| SCHEMBL1575411 | 0.92 | GAA (0.32) | GAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180112132-A1 | LIQUID CRYSTAL COMPOUNDS OF CYCLOALKYL-CONTAINING DIBENZOFURAN DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIAL CO.,LTD (CN) | 2018-04-26 | — | — | US | disclosed |
| US-9540565-B2 | Liquid crystal compounds containing dibenzopyran derivatives of naphthenic base and application thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20160230092-A1 | LIQUID CRYSTAL COMPOUNDS CONTAINING DIBENZOPYRAN DERIVATIVES OF NAPHTHENIC BASE AND APPLICATION THEREOF | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD (CN) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180112132-A1 | LIQUID CRYSTAL COMPOUNDS OF CYCLOALKYL-CONTAINING DIBENZOFURAN DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, WASF2, NOTUM | GAA 4571/4885MAPT 2141/4885MEN1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.